Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that the U.S. Food and Drug Administration (FDA) has removed the clinical hold on patient enrollment and dosing of PEGPH20 in SWOG's ongoing Phase 1b/2 clinical trial (S1313). The trial is...
By Samreen Agha:
The shares of Halozyme Therapeutics, Inc. (HALO) were up almost 7.5% afterhours following the news of FDA's approval of Halozyme and Baxter International's (BAX) HyQvia, on September 13, 2014. Come Monday the shares came tumbling...
By Emerging Equities:
Halozyme Therapeutics Inc. (NASDAQ:HALO) recently announced that the FDA granted a Fast Track Designation for its PEGPH20 program in metastatic pancreatic cancer. It is still too early to speculate on a potential approval,...
DEERFIELD (dpa-AFX) - Baxter International Inc (BAX) and Halozyme
Therapeutics Inc (HALO) said Friday the United States Food and Drug
Administration approved Baxter's subcutaneous treatment for adult patients with
By Mark Kroenke:
Antibiotic resistance is a problem. There is no question that novel compounds are needed, and Congress has attempted to jump start development of new anti-infectives by passing the GAIN act which went into effect October 1st,...
Halozyme Therapeutics, Inc.
(NASDAQ: HALO) today announced that the U.S. Food and Drug Administration
(FDA) has granted Fast Track designation for Halozyme's program
investigating PEGPH20 (PEGylated recombinant human hyaluronidase)...
Halozyme Therapeutics (NASDAQ:HALO)
Q2 2014 Earnings Call
August 11, 2014 4:30 pm ET
Schond Greenway -
Helen I. Torley - Chief Executive Officer, President and Director
David A. Ramsay - Chief Financial Officer,...
Oops! Unable to complete your request. Please refresh your browser.
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article.